Commerzbank Ag Reiterates “€76.00” Price Target for MorphoSys AG (MOR)

Commerzbank Ag set a €76.00 ($88.37) price target on MorphoSys AG (ETR:MOR) in a research report released on Tuesday, November 7th. The brokerage currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on MOR. Independent Research GmbH set a €77.00 ($89.53) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Monday, August 7th. Deutsche Bank AG set a €90.00 ($104.65) price objective on shares of MorphoSys AG and gave the stock a buy rating in a report on Monday, August 7th. J P Morgan Chase & Co set a €62.00 ($72.09) target price on shares of MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Goldman Sachs Group, Inc. (The) set a €55.00 ($63.95) target price on shares of MorphoSys AG and gave the company a neutral rating in a report on Friday, August 4th. Finally, Berenberg Bank set a €68.00 ($79.07) target price on shares of MorphoSys AG and gave the company a buy rating in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. MorphoSys AG currently has a consensus rating of Buy and a consensus price target of €81.25 ($94.48).

Shares of MorphoSys AG (ETR MOR) opened at €79.25 ($92.15) on Tuesday. MorphoSys AG has a 1-year low of €40.10 ($46.63) and a 1-year high of €82.20 ($95.58).

TRADEMARK VIOLATION NOTICE: “Commerzbank Ag Reiterates “€76.00” Price Target for MorphoSys AG (MOR)” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/11/19/commerzbank-ag-analysts-give-morphosys-ag-mor-a-76-00-price-target.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply